Here's How Much $1000 Invested In McKesson 5 Years Ago Would Be Worth Today - McKesson ( NYSE:MCK )
McKesson ( NYSE:MCK ) has outperformed the market over the past 5 years by 24.3% on an annualized basis producing an average annual return of 36.95%. Currently, McKesson has a market capitalization of $106.89 billion.
Freeport-McMoRan, Cisco And Teradyne: CNBC's 'Final Trades' - Cisco Systems ( NASDAQ:CSCO ) , Freeport-McMoRan ( NYSE:FCX )
On CNBC's "Halftime Report Final Trades," Bryn Talkington, managing partner of Requisite Capital Management, named Freeport-McMoRan Inc. ( NYSE:FCX ) as her final trade.
6 Healthcare Stocks With Strong Upward Momentum - Cardinal Health ( NYSE:CAH ) , Abivax ( NASDAQ:ABVX )
Out with the old ( tech ) , in with the new ( healthcare ) . After several volatile weeks, it appears a full-fledged rotation has begun with investors fleeing previously high-flying tech winners in favor of underserved healthcare stocks.
Is CONMED ( CNMD ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why McKesson ( MCK ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson Corporation ( MCK ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why McKesson ( MCK ) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
4 Value Stocks With Strong Interest Coverage as Markets Rebound
As Wall Street rebounds on hopes of a shutdown resolution, investors turn to value picks like LTH, CAH, MCK and FLS with strong interest coverage ratios.
Is First Trust Consumer Staples AlphaDEX ETF ( FXG ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Should iShares MSCI USA Min Vol Factor ETF ( USMV ) Be on Your Investing Radar?
Style Box ETF report for ...
Here is Why Growth Investors Should Buy McKesson ( MCK ) Now
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Brokers Suggest Investing in McKesson ( MCK ) : Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), McKesson (MCK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
SOLV Gains on Q3 Earnings & Sales Beat, Raises '25 EPS Outlook
Solventum posts strong Q3 results with a revenue and earnings beat, lifts 2025 EPS guidance on solid MedSurg and HIS growth.
Pediatrix Medical Q3 Earnings Beat Estimates on Declining Expenses
MD's Q3 profit tops on lower expenses and improved patient acuity, driving earnings past estimates despite softer revenues.
McKesson ( MCK ) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
MCK Q2 Earnings Beat, Sales Miss, '26 EPS View Up, Stock Down
McKesson posts a strong Q2 earnings beat but a slight sales miss, lifts its 2026 EPS outlook on solid specialty and tech segment growth.
McKesson ( MCK ) Surpasses Q2 Earnings Estimates
McKesson (MCK) delivered earnings and revenue surprises of +10.54% and -1.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Lifevantage ( LFVN ) Q1 Earnings Top Estimates
Lifevantage (LFVN) delivered earnings and revenue surprises of +5.88% and -10.92%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Solventum to Post Q3 Earnings: Is a Beat Likely for the Stock?
Solventum's Q3 results may reflect softer sales and tariff impacts, though pricing discipline and core growth drivers likely aided margins.
Will Strong Segmental Performance Drive MCK's Top Line in Q2?
McKesson's Q2 results may show steadier growth as strong U.S. pharmaceutical and RxTS momentum drive its expanding top line.
Can Sustained Product Demand Drive BDX Stock Before Q4 Earnings?
BD rides high on product demand across segments, but fourth-quarter fiscal 2025 results may face pressure from global market dynamics.
4 Resilient Dental Supply Players Positioned to Withstand Tariff Risks
Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.
Ahead of McKesson ( MCK ) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
Earnings Preview: Dentsply International ( XRAY ) Q3 Earnings Expected to Decline
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health ( CAH ) Surpasses Q1 Earnings and Revenue Estimates
Cardinal (CAH) delivered earnings and revenue surprises of +15.38% and +8.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
McKesson ( MCK ) Reports Next Week: Wall Street Expects Earnings Growth
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Much You Would Have Made Owning McKesson Stock In The Last 5 Years - McKesson ( NYSE:MCK )
McKesson ( NYSE:MCK ) has outperformed the market over the past 5 years by 23.95% on an annualized basis producing an average annual return of 39.7%. Currently, McKesson has a market capitalization of $101.25 billion.
McKesson ( MCK ) Upgraded to Strong Buy: Here's What You Should Know
McKesson (MCK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Baxter Q3 Preview: Can Core Segments Deliver Another Solid Quarter?
Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
McKesson ( MCK ) Surpasses Market Returns: Some Facts Worth Knowing
McKesson (MCK) reached $801.67 at the closing of the latest trading day, reflecting a +1.1% change compared to its last close.
Will SYK's Q3 Results Reflect MedSurg Strength & Rebound in Orthopaedics?
Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.
Pharma, Specialty Units Likely to Drive Cardinal Health's Q1 Earnings
CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.
McKesson Corporation ( MCK ) Is a Trending Stock: Facts to Know Before Betting on It
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Will RVTY Q3 Earnings Reflect Segmental Strength Amid Rising Demand?
RVTY's third-quarter results are likely to reflect strong performance in the Life Sciences segment. However, the Diagnostic segment is set to face challenges in China.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
AUSTIN, Texas, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Cassava Sciences, Inc. ( NASDAQ: SAVA, "Cassava", the "Company" ) , a biotechnology company focused on developing novel, investigational treatments for central nervous system ( CNS ) disorders such as Tuberous Sclerosis Complex ( TSC ) -related ...
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors - Cassava Sciences ( NASDAQ:SAVA )
AUSTIN, Texas, Oct. 22, 2025 ( GLOBE NEWSWIRE ) -- Cassava Sciences, Inc. ( NASDAQ:SAVA, "Cassava", the "Company" ) ) , a biotechnology company focused on developing novel, investigational treatments for central nervous system ( CNS ) disorders such as Tuberous Sclerosis Complex ( TSC ) -related ...
McKesson ( MCK ) Surpasses Market Returns: Some Facts Worth Knowing
McKesson (MCK) reached $786 at the closing of the latest trading day, reflecting a +1.36% change compared to its last close.
WST Q3 Earnings Preview: Can GLP-1 Momentum Outweigh Margin Pressure?
West Pharma's Q3 numbers hinge on robust GLP-1 and biologics demand, but labor constraints, tariffs, and plant shutdowns could test its margin resilience.
The Zacks Analyst Blog Highlights UBS, Newmont, McKesson and The Cato
Zacks spotlights UBS, Newmont, McKesson, and Cato, four companies showing strong performance across finance, gold mining, healthcare distribution, and retail.
Top Research Reports for UBS, Newmont & McKesson
UBS advances on solid earnings and integration progress, while Newmont and McKesson deliver strong gains through expansion and operational efficiency.
Why McKesson ( MCK ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson ( MCK ) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, McKesson (MCK) stood at $781.9, denoting a +1.61% move from the preceding trading day.
Here's Why McKesson ( MCK ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
If You Invested $1000 in McKesson a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Here's How Much You Would Have Made Owning McKesson Stock In The Last 10 Years - McKesson ( NYSE:MCK )
McKesson ( NYSE:MCK ) has outperformed the market over the past 10 years by 2.25% on an annualized basis producing an average annual return of 14.73%. Currently, McKesson has a market capitalization of $95.25 billion.
Investors Heavily Search McKesson Corporation ( MCK ) : Here is What You Need to Know
McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio
MCK is transforming from a traditional distributor into a specialty-driven healthcare solutions leader, focusing on oncology, biopharma services and automation while preparing to separate its Medical-Surgical unit.
